Inspire Medical Systems, Inc.

NYSE:INSP

Medical - Devices

Healthcare
$58.11 +1.24%

+$0.51 today

Market cap
$1.68B
Beta
0.73
P/E (TTM)
9.1
EPS (TTM)
$4.57
52W Low $38.91High $147.03

Volume 0.51M

Average 1.13M

INSP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Inspire Medical Systems, Inc.NYSE: INSP

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $24.7M fell 5.8% year over year, ahead of the -9.7% change in trailing-twelve-month research & development. Sequentially, it fell 4.4% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.

Context

  • Research & development amounted to 11.3% of revenue in FY2025, down 2.9 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -5.8% holds above the trailing-twelve-month pace of -9.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$24.7M-4.4% QoQ
Last fiscal yearDec 2025
$103.17M-9.6% YoY
LTMJun 2026
$99.68M-9.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.8%——
1 year-9.6%——
3-year CAGR+14.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
103.17M USD
Year-over-year change
-9.6%
4-year CAGR
+28.9%

Research & Development vs competitors

How INSP compares with its peers on the latest reported figures

  • INSP's LTM Jun 2026 research & development of $99.68M is the 2nd highest of the 9 companies compared; the peer median is $23.6M.
  • Its year-over-year change of -9.7% is the 5th highest of 6, against a peer median of +2.5%.
  • Research & development amounts to 11.1% of revenue for INSP, versus a peer median of 4.1%.
INSP Competitors Peer median
Research & Development for INSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$497M +2.5%+22.0%424.8%
INSPInspire Medical Systems, Inc.LTM Jun 2026$99.68M -9.7%+14.5%11.1%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$73.13M +11.5%+35.0%22.7%
ITGRInteger Holdings CorporationLTM Jul 2026$48.58M -4.7%-8.1%2.6%
AORTArtivion, Inc.LTM Mar 2026$33.1M +17.2%-7.3%7.2%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$14.1M -9.9%+2.1%5.5%
ARDTArdent Health Partners, LLCLTM Mar 2026$0 ——0.0%
ADUSAddus HomeCare CorporationLTM Jun 2026$0 ——0.0%
BKDBrookdale Senior Living Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding INSP) $23.6M+2.5%+2.1%4.1%

Competitors are the stored peer set for INSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue233.39M407.86M624.8M802.8M911.98M
Cost of Revenue33.28M66.12M96.58M122.99M133.23M
Gross Profit200.12M341.74M528.22M679.82M778.76M
Gross Margin85.7%83.8%84.5%84.7%85.4%
Research & Development37.35M68.65M116.54M114.13M103.17M
Selling, General & Admin202.62M320.69M451.96M529.61M624.64M
Operating Expenses239.97M389.33M568.49M643.74M727.8M
Depreciation & Amortization1.22M1.86M2.85M6.55M13.96M
EBITDA(38.62M)(40.73M)(17.06M)65.03M79.79M
EBITDA Margin-16.5%-10.0%-2.7%8.1%8.7%
Operating Income(39.85M)(47.59M)(40.27M)36.08M50.95M
Operating Margin-17.1%-11.7%-6.4%4.5%5.6%
Interest Income125K5.05M20.56M23.25M17.54M
Interest Expense2.13M1.68M022K137K
Other Income / Expenses(2.12M)3.32M20.37M22.37M14.74M
Income Before Tax(41.97M)(44.27M)(19.91M)58.45M65.7M
Pre-Tax Margin-18.0%-10.9%-3.2%7.3%7.2%
Income Tax Expense72K613K1.25M4.94M(79.73M)
Net Income(42.04M)(44.88M)(21.15M)53.51M145.42M
Net Margin-18.0%-11.0%-3.4%6.7%15.9%
EPS (Basic)(1.54)(1.60)(0.72)1.804.95
EPS (Diluted)(1.54)(1.60)(0.72)1.754.89
Weighted Avg Shares27.26M28.07M29.3M29.76M29.37M
Weighted Avg Shares (Diluted)27.26M28.07M29.3M30.54M29.76M

Inspire Medical Systems, Inc.

NYSE:INSP

Intrinsic Alpha fair value

Locked

Current Price

$58.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.